Tuesday, October 12, 2004
Not News
In news that should not surprise anyone who's been paying attention, not to mention just plain paying, drug companies spend more money on stock dividends and buybacks than on R+D. This is not as appalling as the fact that they spend more on advertising than on R+D, but considering their relatively poor stock performance of late, it's pretty bad.
Comments:
Post a Comment
